Cargando…
Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors
Current guidelines for the management of acute myocardial infarction (AMI) recommend potent P2Y12 inhibitors rather than clopidogrel to prevent ischemic events. However, their ischemic benefits are offset by an increased major bleeding risk. We compared the efficacy and safety of triple antiplatelet...
Autores principales: | Byun, Sungwook, Lee, Su Nam, Lim, Sungmin, Choo, Eun Ho, Choi, Ik Jun, Kim, Chan Joon, Moon, Donggyu, Park, Mahn-Won, Park, Chul Soo, Ahn, Youngkeun, Jeong, Myung-Ho, Chang, Kiyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693255/ https://www.ncbi.nlm.nih.gov/pubmed/36431333 http://dx.doi.org/10.3390/jcm11226856 |
Ejemplares similares
-
Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022) -
Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis
por: Uchiyama, Shinichiro, et al.
Publicado: (2021) -
Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021) -
Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study
por: Seo, Woo‐Keun, et al.
Publicado: (2021) -
Ultra-Early Combination Antiplatelet Therapy with Cilostazol for the Prevention of Branch Atheromatous Disease: A Multicenter Prospective Study
por: Kimura, Teruo, et al.
Publicado: (2016)